Floatz logo

Therapeutic Asset Ratings

200 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Duvelisib
Richter Transformation
Ruijin HospitalP1/2CCC (49)
BEBT 908
Acute Lymphoblastic Leukemia
Ruijin HospitalP2CCC (48)
Serplulimab
Colon Carcinoma
Ruijin HospitalP2CCC (48)
Umbilical Cord Derived Mesenchymal Stem Cells Exosomes
Frontotemporal Dementia
Ruijin HospitalP1/2CCC (48)
DALPICICLIB ISETIONATE
Pancreatic Cancer
Ruijin HospitalP2CC (46)
Inotuzumab Ozogamicin
Adult Acute Lymphoblastic Leukemia
Ruijin HospitalP1CC (46)
5-azacytidine
Refractory
Ruijin HospitalP1/2CC (45)
cs01
Locally Advanced or Metastatic Solid Tumors
Ruijin HospitalP1/2CC (45)
Decitabine
Refractory
Ruijin HospitalP1/2CC (45)
Golidocitinib
Refractory
Ruijin HospitalP1/2CC (45)
ibi363
Malignant Pancreatic Neoplasm
Ruijin HospitalP1/2CC (45)
Tucidinostat
Refractory
Ruijin HospitalP1/2CC (45)
Zeprumetostat
Refractory
Ruijin HospitalP1/2CC (45)
Lcar-Hl30 Cells
Hodgkins Lymphoma
Ruijin HospitalP1CC (43)
ly007
B-Cell Non-Hodgkin Lymphoma
Ruijin HospitalP1CC (43)
Neoantigen Personalized Cancer Vaccine
Digestive System Neoplasm
Ruijin HospitalP1CC (43)
Neoantigen Personalized Cancer Vaccine
Neoplasm
Ruijin HospitalP1CC (43)
ntf001
Amyotrophic Lateral Sclerosis
Ruijin HospitalP1CC (43)
Obinutuzumab
the Efficacy and Safety
Ruijin HospitalP1CC (43)
pd-1 knockout engineered t cells
Tumor Infiltrating Lymphocytes
Ruijin HospitalP1CC (43)
pd1-til
Tumor Infiltrating Lymphocytes
Ruijin HospitalP1CC (43)
Personalized Neoantigen Tumor Vaccine
B-Cell Non-Hodgkin Lymphoma
Ruijin HospitalP1CC (43)
Sonrotoclax
the Efficacy and Safety
Ruijin HospitalP1CC (43)
Zanubrutinib
the Efficacy and Safety
Ruijin HospitalP1CC (43)
Clozapine
Clozapine
Ruijin HospitalEarly P1CC (43)
Showing 126 to 150 of 200 assets
PreviousPage 6 of 8Next